MARSHALL WACE, LLP - AEGLEA BIOTHERAPEUTICS INC ownership

AEGLEA BIOTHERAPEUTICS INC's ticker is AGLE and the CUSIP is 00773J103. A total of 87 filers reported holding AEGLEA BIOTHERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is - and the average weighting 0.2%.

Quarter-by-quarter ownership
MARSHALL WACE, LLP ownership history of AEGLEA BIOTHERAPEUTICS INC
ValueSharesWeighting
Q1 2022$355,000
+80.2%
154,175
+270.4%
0.00%
Q4 2021$197,000
-92.2%
41,624
-86.8%
0.00%
-100.0%
Q3 2021$2,511,000
-44.6%
315,823
-51.5%
0.01%
-52.4%
Q2 2021$4,534,000
-51.9%
651,403
-45.3%
0.02%
-51.2%
Q1 2021$9,435,000
-3.6%
1,191,239
-4.2%
0.04%
-18.9%
Q4 2020$9,784,000
+11.1%
1,243,250
+0.1%
0.05%
-5.4%
Q3 2020$8,809,000
-23.7%
1,242,427
-0.5%
0.06%
-30.9%
Q2 2020$11,552,000
+195.4%
1,248,915
+48.8%
0.08%
+107.7%
Q1 2020$3,911,000
-38.6%
839,160
+0.7%
0.04%
-11.4%
Q4 2019$6,367,000
+3.4%
833,407
+4.1%
0.04%
-8.3%
Q3 2019$6,157,000
+36.4%
800,607
+21.5%
0.05%
+29.7%
Q2 2019$4,513,000
-25.4%
658,698
-12.4%
0.04%
+27.6%
Q1 2019$6,052,000751,8060.03%
Other shareholders
AEGLEA BIOTHERAPEUTICS INC shareholders Q1 2021
NameSharesValueWeighting ↓
UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO 279,678$2,587,00010.00%
Aisling Capital Management LP 1,691,151$15,643,0005.97%
Samsara BioCapital, LLC 967,500$8,949,0002.88%
Bain Capital Life Sciences Investors, LLC 2,700,000$24,975,0002.62%
Soleus Capital Management, L.P. 369,852$3,421,0001.95%
Nantahala Capital Management 3,204,830$29,645,0000.89%
Lion Point Capital, LP 300,000$2,775,0000.67%
Abingworth LLP 240,500$2,221,0000.62%
Sio Capital Management, LLC 211,104$1,953,0000.57%
Orbimed Advisors 4,015,524$37,144,0000.52%
View complete list of AEGLEA BIOTHERAPEUTICS INC shareholders